Omeros (NASDAQ:OMER) executives highlighted two “major successes” in the fourth quarter of 2025 that they said marked a ...

Q4 2025 Earnings Call March 31, 2026 4:30 PM EDTCompany ParticipantsGregory Demopulos - Co-Founder, Chairman, CEO ...

Immunoglobulin A (IgA) nephropathy results from the accumulation of IgA-containing immune complexes (IgA-ICs) and aberrant ...

Immunoglobulin A (IgA) nephropathy is an autoimmune disease characterized by the deposition of circulating IgA-containing immune complexes (IgA-ICs ...

Immunoglobulin A (IgA) nephropathy is an autoimmune disease characterized by the deposition of circulating IgA-containing immune complexes (IgA-ICs) in the glomerular mesangium, leading to mesangial ...

Fabhalta lowered likelihood of progression to kidney failure by 43% in APPLAUSE-IgAN study140.7% of patients on Fabhalta demonstrated sustained reduction of protein in urine over two years1Fabhalta gr ...

This article is authored by Rahul Munjal, founder chairman, Hero Future Energies.

Novartis announces positive final two-year results from phase III APPLAUSE-IgAN study of Fabhalta in IgA nephropathy: Basel Tuesday, March 31, 2026, 12:00 Hrs [IST] Novartis annou ...

Fabhalta lowered likelihood of progression to kidney failure by 43% in APPLAUSE-IgAN study140.7% of patients on Fabhalta demonstrated sustained reduction of protein in urine over two years1Fabhalta ...

By Caroline TREFAULT As Africa’s economies continue to diversify and grow at around 4% year-on-year on average, moving goods across the continent is becoming more complex, time-sensitive, and ...

Food Frontier and Cellular Agriculture Australia have merged to advance research, policy breakthroughs, and regulatory ...